Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion type Assertion NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_head.
- NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion description "[To evaluate the effect of shortened duration of pegylated interferon (PEG-IFN) and ribavirin (RIB) treatment on sustained virological response (SVR) rates in treatment-naomicronve patients with chronic hepatitis due to genotype 2 or 3 hepatitis C virus (HCV) infection and high pre-treatment viral load (>800,000 IU/mL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_provenance.
- NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion evidence source_evidence_literature NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_provenance.
- NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion SIO_000772 18227568 NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_provenance.
- NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion wasDerivedFrom befree-2016 NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_provenance.
- NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_assertion wasGeneratedBy ECO_0000203 NP652267.RAcpCVh1Aj5vLU2mgXnaL0yexICoEG02pZ768PAjhfEYY130_provenance.